511 related articles for article (PubMed ID: 26866723)
1. Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome.
Maria NI; van Helden-Meeuwsen CG; Brkic Z; Paulissen SM; Steenwijk EC; Dalm VA; van Daele PL; Martin van Hagen P; Kroese FG; van Roon JA; Harkin A; Dik WA; Drexhage HA; Lubberts E; Versnel MA
Arthritis Rheumatol; 2016 Jul; 68(7):1688-99. PubMed ID: 26866723
[TBL] [Abstract][Full Text] [Related]
2. Umbilical cord mesenchymal stem cells inhibit the differentiation of circulating T follicular helper cells in patients with primary Sjögren's syndrome through the secretion of indoleamine 2,3-dioxygenase.
Liu R; Su D; Zhou M; Feng X; Li X; Sun L
Rheumatology (Oxford); 2015 Feb; 54(2):332-42. PubMed ID: 25169988
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren's syndrome.
Pertovaara M; Raitala A; Uusitalo H; Pukander J; Helin H; Oja SS; Hurme M
Clin Exp Immunol; 2005 Oct; 142(1):155-61. PubMed ID: 16178870
[TBL] [Abstract][Full Text] [Related]
4. Increased Indoleamine 2,3-Dioxygenase Levels at the Onset of Sjögren's Syndrome in SATB1-Conditional Knockout Mice.
Tanaka Y; Onozato M; Mikami T; Kohwi-Shigematsu T; Fukushima T; Kondo M
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576286
[TBL] [Abstract][Full Text] [Related]
5. Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells.
Que Z; Zou F; Zhang A; Zheng Y; Bi L; Zhong J; Tian J; Liu J
Int Immunopharmacol; 2014 Nov; 23(1):192-204. PubMed ID: 25138378
[TBL] [Abstract][Full Text] [Related]
6. Expansion of CD4+CD25-GITR+ regulatory T-cell subset in the peripheral blood of patients with primary Sjögren's syndrome: correlation with disease activity.
Alunno A; Nocentini G; Bistoni O; Petrillo MG; Bartoloni Bocci E; Ronchetti S; Lo Vaglio E; Riccardi C; Gerli R
Reumatismo; 2012 Dec; 64(5):293-8. PubMed ID: 23256104
[TBL] [Abstract][Full Text] [Related]
7. Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c
Woodberry T; Loughland JR; Minigo G; Burel JG; Amante FH; Piera KA; McNeil Y; Yeo TW; Good MF; Doolan DL; Engwerda CR; McCarthy JS; Anstey NM
Infect Immun; 2017 Jun; 85(6):. PubMed ID: 28320838
[No Abstract] [Full Text] [Related]
8. Fatigue in Primary Sjögren's Syndrome: Clinical, Laboratory, Psychometric, and Biologic Associations.
Karageorgas T; Fragioudaki S; Nezos A; Karaiskos D; Moutsopoulos HM; Mavragani CP
Arthritis Care Res (Hoboken); 2016 Jan; 68(1):123-31. PubMed ID: 26315379
[TBL] [Abstract][Full Text] [Related]
9. Kynurenine production mediated by indoleamine 2,3-dioxygenase aggravates liver injury in HBV-specific CTL-induced fulminant hepatitis.
Ohtaki H; Ito H; Ando K; Ishikawa T; Hoshi M; Ando T; Takamatsu M; Hara A; Moriwaki H; Saito K; Seishima M
Biochim Biophys Acta; 2014 Sep; 1842(9):1464-71. PubMed ID: 24768802
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.
Bonanno G; Mariotti A; Procoli A; Folgiero V; Natale D; De Rosa L; Majolino I; Novarese L; Rocci A; Gambella M; Ciciarello M; Scambia G; Palumbo A; Locatelli F; De Cristofaro R; Rutella S
J Transl Med; 2012 Dec; 10():247. PubMed ID: 23232072
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T-Cells Mediate IFN-α-Induced Resistance against Antigen-Induced Arthritis.
Chenna Narendra S; Chalise JP; Biggs S; Kalinke U; Magnusson M
Front Immunol; 2018; 9():285. PubMed ID: 29515584
[TBL] [Abstract][Full Text] [Related]
12. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation.
Chen W; Liang X; Peterson AJ; Munn DH; Blazar BR
J Immunol; 2008 Oct; 181(8):5396-404. PubMed ID: 18832696
[TBL] [Abstract][Full Text] [Related]
13. The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.
Shibata Y; Hara T; Nagano J; Nakamura N; Ohno T; Ninomiya S; Ito H; Tanaka T; Saito K; Seishima M; Shimizu M; Moriwaki H; Tsurumi H
PLoS One; 2016; 11(1):e0146279. PubMed ID: 26727596
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome.
Alunno A; Petrillo MG; Nocentini G; Bistoni O; Bartoloni E; Caterbi S; Bianchini R; Baldini C; Nicoletti I; Riccardi C; Gerli R
Rheumatology (Oxford); 2013 Aug; 52(8):1387-96. PubMed ID: 23674818
[TBL] [Abstract][Full Text] [Related]
15. Human primary CD4 + T cells activated in the presence of IFN-alpha 2b express functional indoleamine 2,3-dioxygenase.
Curreli S; Romerio F; Mirandola P; Barion P; Bemis K; Zella D
J Interferon Cytokine Res; 2001 Jun; 21(6):431-7. PubMed ID: 11440641
[TBL] [Abstract][Full Text] [Related]
16. IDO expressing dendritic cells suppress allograft rejection of small bowel transplantation in mice by expansion of Foxp3+ regulatory T cells.
Xie FT; Cao JS; Zhao J; Yu Y; Qi F; Dai XC
Transpl Immunol; 2015 Oct; 33(2):69-77. PubMed ID: 26002283
[TBL] [Abstract][Full Text] [Related]
17. Blockage of indoleamine 2,3-dioxygenase regulates Japanese encephalitis via enhancement of type I/II IFN innate and adaptive T-cell responses.
Kim SB; Choi JY; Uyangaa E; Patil AM; Hossain FM; Hur J; Park SY; Lee JH; Kim K; Eo SK
J Neuroinflammation; 2016 Apr; 13(1):79. PubMed ID: 27090635
[TBL] [Abstract][Full Text] [Related]
18. The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren's syndrome and systemic sclerosis.
Legány N; Berta L; Kovács L; Balog A; Toldi G
Immunol Res; 2017 Jun; 65(3):622-629. PubMed ID: 27878564
[TBL] [Abstract][Full Text] [Related]
19. Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.
Nakamura N; Hara T; Shimizu M; Mabuchi R; Nagano J; Ohno T; Kochi T; Kubota M; Shirakami Y; Goto N; Ito H; Saito K; Tanaka T; Moriwaki H; Tsurumi H
Int J Hematol; 2015 Sep; 102(3):327-34. PubMed ID: 26243621
[TBL] [Abstract][Full Text] [Related]
20. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
Chevolet I; Schreuer M; Speeckaert R; Neyns B; Hoorens I; van Geel N; Krüse V; Hennart B; Allorge D; Van Gele M; Brochez L
Melanoma Res; 2015 Aug; 25(4):357-61. PubMed ID: 26050145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
